Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.

Rutsaert, Sofie; Steens, Jean-Marc; Gineste, Paul; Cole, Basiel; Kint, Sam; Barrett, P Noel; Tazi, Jamal; Scherrer, Didier; Ehrlich, Hartmut J; Vandekerckhove, Linos

Rutsaert, Sofie; Steens, Jean-Marc; Gineste, Paul; Cole, Basiel; Kint, Sam; Barrett, P Noel; Tazi, Jamal; Scherrer, Didier; Ehrlich, Hartmut J; Vandekerckhove, Linos.

Afiliação

Rutsaert S; HIV Cure Research Center, Department of Internal Medicine, Ghent University, Belgium.
Steens JM; ABIVAX, Paris, France.
Gineste P; ABIVAX, Paris, France.
Cole B; HIV Cure Research Center, Department of Internal Medicine, Ghent University, Belgium.
Kint S; HIV Cure Research Center, Department of Internal Medicine, Ghent University, Belgium.
Barrett PN; Independent Consultant, c/o ABIVAX, Paris, France.
Tazi J; Institut de Génétique Moléculaire, University of Montpellier, France.
Scherrer D; ABIVAX, Paris, France.
Ehrlich HJ; ABIVAX, Paris, France.
Vandekerckhove L; HIV Cure Research Center, Department of Internal Medicine, Ghent University, Belgium.

J Virus Erad ; 5(1): 10-22, 2019 Jan 01.

Article em En | MEDLINE | ID: mdl-30800421

Palavras-chave

ABX464, safety, tolerability, HIV-1, Phase IIa study, HIV-1 reservoirs, viral rebound

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google